Physician profile
Richard Solga
NPI 1477643450
$12,591.76
in general payments reported to CMS, 2019-2025
14 companies · $4,205 in 2025
The $4,205 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $288 · 2022: $2,077 · 2023: $3,012 · 2024: $3,010 · 2025: $4,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,828 · Education: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,828.13 |
| Education | $398.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,151.89 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,909.18 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $1,693.81 | 2022-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $1,620.04 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $1,513.99 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,266.76 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $683.14 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $606.82 | 2023-2025 | Auvelity |
| Lundbeck LLC | $334.76 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $334.37 | 2022-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $249.75 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $115.98 | 2024-2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $99.20 | 2021-2022 | |
| Almatica Pharma LLC | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Solga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.